ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure
Iron-Deficiency Chronic Heart Failure
Indication: Iron Deficiency in Heart Failure
Sponsor: Pharmacosmos · P-Monofer-CHF-02 · NCT06929806
About this study
Phase 3 trial of ferric derisomaltose (intravenous iron) versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure. ICONIC-HF measures the impact of IV iron supplementation on HF outcomes.
To evaluate whether intravenous ferric derisomaltose improves outcomes versus no intravenous iron in adults with symptomatic chronic heart failure and iron deficiency.
Study details
- Sponsor
- Pharmacosmos
- Protocol
- P-Monofer-CHF-02
- Phase
- Phase 3
- Indication
- Iron-Deficiency Chronic Heart Failure
- Status
- Active — enrolling
High-level eligibility
- Adults with symptomatic chronic heart failure
- Confirmed iron deficiency (TSAT <20% or ferritin criteria)
- Stable on guideline-directed therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit at amavita Heart and Vascular Health®.
For patients
Read: Iron Deficiency in Heart Failure Clinical Trials — A Patient's Guide →
I'm a sponsor / CRO →
Discuss enrollment, capacity, and operational fit.
I might be eligible — call (786) 703-5941 →
Free, no-obligation pre-screen in English / Spanish / Haitian Creole.
Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.